Crinetics Pharmaceuticals, Inc.
CRNX
Hisse Senetlerindeki Sıralama
#2246
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Hisse Fiyatı
$84.95
Son senkronizasyon: 2026-09-01
Piyasa Değeri
$9.00B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
98.25%
Ülke
US
Ticaret Crinetics Pharmaceuticals, Inc. (CRNX)
Kategori
Healthcare
Crinetics Pharmaceuticals, Inc. (CRNX) için kazanç
Jun 2026 itibarıyla kazanç TTM: $-501.43M
Crinetics Pharmaceuticals, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-501.43M'dir. 2023 yılında şirket $-214.53M kazanç elde etti, bu 2022 yılındaki $-163.92M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Crinetics Pharmaceuticals, Inc. için kazanç geçmişi 2016 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-501.43M | 68.03% |
| 2024 | $-298.41M | 39.10% |
| 2023 | $-214.53M | 30.88% |
| 2022 | $-163.92M | 52.28% |
| 2021 | $-107.64M | 45.83% |
| 2020 | $-73.81M | 46.39% |
| 2019 | $-50.42M | 85.96% |
| 2018 | $-27.12M | 196.11% |
| 2017 | $-9.16M | 52.13% |
| 2016 | $-6.02M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -1,151.98% |
US
|
|
| $-3.09B | 515.64% |
US
|
|
| $-4.02B | 700.95% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -489.02% |
NL
|
